Jessica Zweig, MD
Pulmonary Disease · Saint Louis, MONPI 1194144303
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (45.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intuitive Surgical at 50.8% of the total. Reporting peaked in 2023 at $13,653 and has fallen 72.3% since, to $3,787 in 2025.
Across 412 payments — averaging $49.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- Actelion Pharmaceuticals US, Inc.$3K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$616
- AstraZeneca$602
- Sanofi$569
- plus $4K from 25 others
What the payments were for
- Consulting fees$2,00010%
- Travel & lodging$1,0945%
- Food & beverage$8,17440%
- Education$9,31045%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $10,447 |
| Actelion Pharmaceuticals US, Inc. | 27 | $2,948 |
| GSK | 117 | $1,298 |
| Regeneron Healthcare Solutions, Inc. | 20 | $616 |
| AstraZeneca | 34 | $602 |
| Sanofi | 19 | $569 |
| Merck | 15 | $502 |
| Bayer | 17 | $445 |
| Insmed, Inc. | 22 | $399 |
| United Therapeutics Corporation | 10 | $341 |
| Novartis | 18 | $316 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $290 |
| Harmony Biosciences LLC | 6 | $254 |
| Electromed, Inc. | 23 | $216 |
| Boehringer Ingelheim | 9 | $211 |
| Grifols USA, LLC | 9 | $181 |
| Amgen | 9 | $180 |
| Mylan Specialty L.p. | 7 | $157 |
| Philips North America LLC | 8 | $149 |
| Shionogi Inc | 4 | $89 |
| Resmed Corp | 3 | $69 |
| Fisher & Paykel Healthcare Inc | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| AbbVie | 2 | $34 |
| Baxter Healthcare | 2 | $31 |
| Ambu Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Noah Medical Corporation | 1 | $23 |
| Rocket Medical LLC | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,578 in reported general payments places this provider in the 85th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 93 | $1,178,414 |
| UptraviSelexipag | 34 | $775,340 |
| AdempasRiociguat | 54 | $739,893 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 125 | $102,635 |
| Fasenra PenBenralizumab | 11 | $63,689 |
| Ambrisentan | 18 | $53,777 |
| Spiriva RespimatTiotropium Bromide | 76 | $45,725 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $41,743 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $39,352 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $37,408 |
| EliquisApixaban | 36 | $29,010 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $14,196 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 33 | $14,065 |
| Tadalafil | 41 | $11,210 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $10,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $2,948 | $1,953,754127 claims |
| BayerAdempas | $445 | $739,89354 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,298 | $194,214288 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $211 | $83,133142 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $602 | $35,08764 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Saint Louis
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Edward CharbekSaint Louis$372K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Murali ChakinalaSaint Louis$172K
- Janet LeeSaint Louis$143K
- Ali SadoughiSaint Louis$87K
- Ramsey HachemSaint Louis$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.